Indol-2-yl ethanones as novel indoleamine 2, 3- 
Introduction
Immunotherapy is a promising novel strategy for cancer treatment. It consists of therapeutic vaccination of cancer patients 40 in order to stimulate their (natural) immune system against cancer cells. This approach, however, showed limited efficacy in vivo. Indeed, cancer cells are able to develop enzymatic mechanisms allowing tumors to resist or escape immune rejection. Among the enzymes involved, the indoleamine 2,3-dioxygenase (IDO; EC 1.13.11.52) represents a crucial actor. 1, 2 IDO is a $45 kDa monomeric extrahepatic cytosolic heme dioxygenase which catalyzes the initial and rate-limiting step in the catabolism of the essential amino acid tryptophan (Trp) along the kynurenine pathway, the de novo biosynthetic route leading 50 to nicotinamide adenine dinucleotide (NAD). 3, 4 IDO is a more promiscuous enzyme than the catalytically related hepatic enzyme tryptophan 2,3-dioxygenase (TDO; EC 1.13.11.11). Apart from both tryptophan enantiomers, IDO substrates are indoleamines such as serotonin, melatonin, and tryptamine. 5 In order for IDO to be catalytically active, it is essential to maintain the heme iron ion in the ferrous (Fe 2+ ) state. As the enzyme is susceptible to autoxidation, a reductant is necessary for preserving the enzymatic activity. Cytochrome b 5 has been demonstrated to play this role in vivo. 6, 7 By depleting Trp locally, IDO blocks the proliferation of T lym-60 phocytes, which are sensitive to Trp shortage. 8 The downstream catabolites of the kynurenine pathway exacerbate this immunosuppressive effect 1 and are also involved in other pathological conditions, particularly in the nervous system. [9] [10] [11] Many human tumors constitutively express IDO. 12 It has been
shown that an increased level of IDO expression in tumor cells is correlated with poor prognosis for survival in cancer. 13, 14 This led to the hypothesis that IDO inhibition might enhance the efficacy of cancer treatments. Indeed, results from in vitro and in vivo studies have suggested an improvement of the efficacy of therapeutic 70 vaccination or chemotherapy by concomitant administration of an IDO inhibitor thus highlighting IDO as an attractive target. 12, 13, [15] [16] [17] Until recently, the best known IDO inhibitors 18 displayed affinities in the micromolar range and comprised mainly Trp derivatives such as 1-methyltryptophan (1MT) 19 (K i = 37 lM) or b-carbolines (K i $0.12 mM). 20 Other indole-based IDO inhibitors, such as brassinin 21, 22 and methylthiohydantoin-tryptophan (MTH-Trp) 13 have been described. The best inhibitor of the brassinin class has a K i of 12 lM but is not Lipinski-compliant due to high 80 hydrophobicity. 22 In 2006, potent IDO inhibitors were isolated from marine invertebrate extracts, 23, 24 leading to two new series of uncompetitive nanomolar inhibitors. 26, 27 However, some of the most active compounds of the original series revealed to be inactive in a yeast-based cellular assay, suggesting poor cell penetration. 7 This test nevertheless provided two new micromolar inhibitors with unknown modes of action. In 1989, 4-phenylimidazole (PIM) was identified as a modestly potent IDO inhibitor. 4, 19 Despite the uncompetitive inhibition 90 kinetics, the authors showed through spectroscopic studies that PIM binds into the active site of IDO. Moreover, they discovered a preferred binding of PIM to the inactive ferric (Fe 3+ ) form of the enzyme, which may explain this apparent discrepancy. The first crystal structure of human IDO complexed with the inhibitor reported later 25 confirmed the binding of PIM in the active site. A recently undertaken structure-based study 26 of PIM-derived molecules prompted by Sugimoto's work confirmed the antecedent findings while providing access to novel inhibitors with low micromolar potencies.
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Recent developments in the field include hypoxic-neoplastic cells-targeting 1MT-tirapazamine hybrids, 27 novel inhibitors obtained from marine sediments (IC 50 % 2 lM), 28 potent competitive inhibitors including a hydroxyamidine chelating motif (IC 50 values down to 60 nM), 29 strong inhibition by modification of cysteine residues by ebselen, 30 sub-micromolar S-benzylisothiourea-based inhibitors active in cells, 31 various potent inhibitors (IC 50 values down to 0.2 lM) discovered by a combination of a docking-based pharmacophore model development and fragment-based drug design (FBDD). 32 
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Despite all these efforts, modestly potent 1MT (K i = 34 lM) 19 remains the only compound to have been passed into clinical trials as an IDO inhibitor so far. 33 This prompted us to search for new scaffolds that could be further optimized with the objective of identifying potent and selective IDO inhibitors. Briefly, a collection of $62,000 structures was downloaded from the ZINC website using Lipinski-style rules for fragments (molecular weight 250, Log P 2.5, number of rotatable bonds 5). 34 These compounds were docked inside the IDO active site and ranked according to their best potential binding. From the 39 compounds that were se-120 lected, bought and assayed on IDO, six derivatives displayed an inhibitory potency >30% at a concentration of 100 lM. Among these, compound 7a, characterized by an indole nucleus substituted in the 2-position by a 2-pyridinyl-ethanone function, was our best hit (IDO IC 50 $65 lM), with an inhibitory potency in the same range as the reference compound 1MT. (Table 1) . Herein we report the synthesis and structure-activity study of compound 7a.
An initial docking study of 7a within the IDO binding cleft was performed by means of the automated GOLD program 35 and re-130 vealed essential features stabilizing 7a in the IDO binding cleft and particularly that (i) the oxygen atom of the ketone function, being situated $2 Å above the plane of the heme, coordinates to the heme iron, (ii) the indole ring is found to be stabilized in the so-called lipophilic A-pocket of IDO. 32 Indeed, this stabilization of the indole residue in Pocket A was already suggested by other groups to explain substrate binding as well as interaction of 1MT. In this position, the 3-pyridyl group is projected towards the entrance of the active site and is stabilized in the aromatic Pocket B through T-shape interactions with Phe163 and Phe226
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( Fig. 1) . Our structural modifications of 7a were focused on exploiting three binding interactions with IDO: (1) the interior of the active site, in particular interactions with C129 and S167 in Pocket A; (2) the active site entrance region (Pocket B) occupied by the N-cyclohexyl-2-aminoethanesulfonic acid (CHES) buffer molecule in a crystal structure; 25 (3) the heme iron binding group. According to the binding orientation of 7a we hoped to achieve interactions in the interior region of the active site (Pocket A) by introducing substituents on the indole ring. The substituents were chosen with a 150 view to balance on one side the lipophilic character of this Pocket introducing groups such as fluorine, bromine, chlorine, methyl; and, on the other side the possibility of forming H-bond interactions with specific amino acids with such substituents as hydroxyl, methoxy, nitro, or trifluoromethoxy. The interaction within Pocket B would be probed by replacement of the 3-pyridyl group of 7a with other (hetero)aromatics. The heme iron binding interaction would be explored by replacement of the ethanone moiety with other linkers between the indole and the aromatic side chain.
Chemistry
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Initial efforts to prepare analogues of compound 7a included attempts to react indole-2-acyl chlorides (Scheme 1, 3, R 00 = Cl) with reagents derived from 3-bromomethylpyridine hydrobromide under various conditions. [36] [37] [38] In fact, all of these approaches revealed to be unsatisfactory, the main difficulty likely being the intrinsic instability of the in situ generated free base 3-bromomethylpyridine which readily oligomerizes. 39 The only strategy allowing access to 7a analogues was the approach originally developed by Sundberg et al., as outlined in Scheme 1. This method involves the LDA effected deprotonation of alkylarene 1 followed by 170 quenching of the in situ generated carbanion with a reactive indole carbonyl compound (3 and 6) at 0°C. Stirring overnight while slowly attaining room temperature followed by aqueous workup, chromatographic purification and crystallization provided the targeted compounds. Accordingly, most of the compounds 7 as well as 8a, 9a, 10a, and 11a were prepared from indole esters (3, R 00 = OMe, OEt) or acyl chlorides (3, R 00 = Cl) when these starting material were commercially available. Otherwise, the necessary indole acyl chloride 3 was prepared by reaction of the commercially available indole-2-180 carboxylic acid 2 in refluxing thionyl chloride. Non-commercially available indole esters 3 were made using the Hemetsberger-Knittel procedure starting from the corresponding a-azidocinnamates 5, which were in turn made by condensation of the substituted benzaldehydes 4 with ethyl azidoacetate under Knoevenagel conditions (Scheme 1). 40, 41 It should be noted that compound 11a (Scheme 1) was prepared in 37% yield using commercial Grignard reagent in lieu of the LDA procedure. Moreover, during the course of this reaction, the tertiary alcohol 16 (inactive in the biological tests; data not shown) was also isolated in 17% yield.
Palladium catalyzed reductions were used to convert benzyloxy-substituted 2-ketoindoles 7n and 7r to their debenzylated counterparts 7o and 7s, respectively. Bis-alcohol 17 was also isolated as a byproduct during the catalytic reduction of 7n. The 5-phenylindole derivative 7l was prepared from the corresponding 5-bromo analogue 7h by a Suzuki cross-coupling with phenylboronic acid (Scheme 1). Finally, after initial unsuccessful attempts to demethylate 8d with boron tribromide (which seemed to cause product decomposition), the 4-hydroxyindole 8e was obtained by reaction of 8d with aluminum trichloride in
For the synthesis of the N-methylated analogue 12a, the required N-methylated indole ester 6 was synthesized by dimethylation of N-unsubstituted indole-2-carboxylic acid 2 (Scheme 1). 42 The catalytic hydrogenation of 7a afforded the hydroxyl derivative 18 (Scheme 2). Compound 19 bearing an ethylene linker between the two aromatic rings was prepared from 7a by a 19 F NMR, LC-MS, and elemental analysis (see Section 5) . In addition, single crystal X-ray diffraction was used to corroborate the structures obtained in these series. The molecular structures of compounds 7a and 7m with displacement ellipsoids drawn at the 50% probability levels are depicted in Figure 2 . It should be noted that for 7m thermal agitation of the trifluoromethoxy side chain led to large displacement ellipsoids for the fluorine atoms. Starting from our hit 7a (IC 50 = 65 lM), we first explored the influence of substitution around the indole ring. From Table 2 it can be observed that introduction of substituents in the 3-(7b), 4-(7c-e), and 7-position (7q) does not generally afford more We next explored the influence of modifying the fragment interacting with Pocket B of the IDO active site. From Table 3 , it can be observed that introductions of an unsubstituted phenyl (11a), a 2-pyridyl (8a) or a 2-pyrazinyl group (10a) in lieu of the 3-pyridyl moiety of 7a slightly improve the IDO inhibitory potency (IC 50 's of 29, 37, and 26 lM, respectively). On the contrary, introduction of a 4-pyridyl moiety (9a) afforded an inactive compound.
IDO inhibition through interaction with the heme iron binding group
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Finally we appraised the importance of the ketone moiety of compound 7a in establishing an interaction with the heme iron. Indeed, reduction of this group (18) or its removal altogether (19) led to inactive compounds thus confirming the requirement for an iron coordinating group (Table 4) . Oxime 20 is endowed with an in vivo inhibitory potency similar to that of ketone 7a but surprisingly, this compound is not active in vitro. This might result from a poor stability of the oxime moiety in the experimental conditions of the assay. Methylating the ethanone link (7v) or its replacement with an amide (21) afforded less potent compounds. led to compounds of roughly equivalent potency, indicating room for further modifications but also a probable lack of close interactions of the inhibitor molecules with the IDO Pocket A interior as described by Rohrig et al. 32 A similar generalization can be applied to the other aromatic moiety and its putative interactions with Pocket B of the IDO. Altogether, it seems no strong H-bond interactions with any of the hydrogen bonding residues in the IDO active site could be established. The presence of an iron chelating group seems to be of crucial importance, since its deletion leads to loss of potency.
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A number of compounds investigated here possess a moderate in vivo activity. The compounds 7f and 7g (with small halogen atoms in the 5-position of the indole moiety) are both endowed with 24% IDO inhibition at a 20 lM concentration in the cellular assay, which indicates reasonable cell penetration. A very similar value was obtained for oxime 20.
In summary, a novel series of compounds with a moderate inhibitory activity against IDO has been identified. Both in vitro and in vivo assays show promising results. Further modifications aiming to achieve more favorable interactions with the enzyme ac-290 tive site are in due course.
Experimental part
Chemistry
General experimental procedures
Chemicals were purchased from commercial suppliers (Acros, Sigma-Aldrich, Maybridge, Apollo) and used without further purification. All solvents were used as purchased from Acros, Sigma-Aldrich, Fisher Scientific and Biosolve. All reactions were performed under an inert argon (Alphagaz 2) atmosphere, unless stated otherwise. Melting points were determined in open capillar-300 ies on a Büchi B-540 capillary melting point apparatus and are uncorrected.
Thin layer chromatography (TLC) was performed on silica gel plates (60F 254 , 0.2 mm thick, Merck) eluting with gradients of ethyl acetate in cyclohexane. The spots were visualized by ultraviolet light (wavelengths 254 and 366 nm). Analytical LC-MS analyses were performed on an Agilent 1100 Series LC-MSD Trap system using UV detection at 254 and 366 nm. MS data were recorded using electrospray ionization (ESI) operating in positive mode. The following two methods were applied: method 1: injection of 10 ll of a 20 lg/mL acetonitrile solution onto a C18-3.5 lm Zorbax SB column (100 Â 3 mm); separation 320 using a gradient (flow rate: 0.5 mL/min) of acetonitrile in acetic acid 0.1% (v/v) in water: 5-95% acetonitrile during 5 min, holding for 3 min, then reversing to 5% acetonitrile during 0.1 min and holding for an additional 5.4 min. Method 2: injection of 10 ll of a 2 lg/mL acetonitrile solution onto a C18-5 lm Agilent LiChrospher 100 column (250 Â 4 mm); separation using a gradient (flow rate: 1.0 mL/min) of acetonitrile in acetic acid 0.1% (v/v) in water: 20-80% acetonitrile during 20 min, holding for 20 min, then reversing to 20% acetonitrile during 0.1 min and holding for an additional 5 min.
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Automated flash chromatography was performed on the Biotage AB (Uppsala, Sweden) SP1 system equipped with prepacked flash KP-Sil silica cartridges eluting with gradients of ethyl acetate in cyclohexane. The peaks were detected by UV absorption at 254 and 320 nm.
The yields refer to combined yields of chromatographically and spectroscopically pure (>95%) compounds and the crops obtained by evaporation of mother liquors. All new compounds were determined to be >95% pure by LC-MS and NMR. The microwave-assisted syntheses were carried out in an Initi-ator 16 single-mode microwave instrument producing controlled irradiation at 2.450 GHz (Biotage AB). Reaction times refer to hold times at the temperatures indicated, not to total irradiation times. The temperature was measured with an IR sensor on the outside of the reaction vessel.
5.1.2. Methods for preparation of indolic intermediates (3 and 6) 5.1.2.1. Indole-2-acyl chlorides (3, R 00 = Cl). Commercial indole-2-carboxylic acid was dissolved in thionyl chloride ($1.5 mL/ mmol) and the suspension was boiled for 15 min, during which 350 time typically a dark green solution was formed. Excess thionyl chloride was removed under reduced pressure and the solid residue was suspended in toluene and the suspension was evaporated to dryness (toluene treatment was repeated three times). The green-grayish solid residues were used without further purification.
Indolic esters by
Hemetsberger-Knittel synthesis (3, R 00 = OEt) 40, 41 . Sodium (4.0 equiv) was dissolved in absolute ethanol (0.5 mL/mmol) and the solution was cooled to À10°C in an ice/ acetone bath. A corresponding benzaldehyde (1.0 equiv) was dis-360 solved in a commercial 25% solution of ethyl azidoacetate in ethanol (2.1 g per mmol of starting benzaldehyde, 4.0 equiv) and this solution was added dropwise to the sodium ethoxide solution during 30 min while the bath temperature was kept at À10°C. The reaction mixtures typically turned into bright yellow suspensions. The stirring was continued until TLC (developing with 15% EtOAc in cyclohexane) indicated completion or the reaction (1.5-2.5 h). If the reaction required more than 1.5 h, the temperature was allowed to rise to 0°C. In one case (5r), the reaction had to be run overnight. The mixtures were partitioned between ethyl acetate 370 and water. The aqueous phase was extracted twice with ethyl acetate and the organic layers were pooled, washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure to provide crude azidoacrylic esters (5) as yellow to orange oils or liquids in a 46-100% yield. These products were suspended in nhexane (6-9 mL/mmol of crude azidoacrylic ester) and subjected to microwave heating at 200°C for 5 min (P = 100-140 W, p = 12-13 bar). The resulting residues were taken into ethyl acetate and evaporated with silica gel. The corresponding indolic esters 3 (yields 19-93%) were purified by chromatography. In one case, a 380 mixture of isomers was obtained. 2-Azido-3-(3-methoxyphenyl)-acrylic acid ethyl ester gave 5-methoxy-1H-indole-2-carboxylic acid ethyl ester (3j) and 7-methoxy-1H-indole-2-carboxylic acid ethyl ester (3q) in a 1:1 ratio (each in a 47% yield).
N-Methylated indolic ester
; methyl 1-methyl-1H-indole-2-carboxylate (6) . Prepared according to a literature procedure. 42 Methyl iodide (5.0 mL, 80.0 mmol) was added to a stirred suspension of anhydrous potassium carbonate (6.3 g, 45.6 mol) and 1H-indole-2-carboxylic acid (2; 5.3 mmol) in dry DMF (6 mL) and the mixture was stirred at 80°C until the reaction was complete as 390 indicated by TLC and/or LC-MS (3-5 days). Upon cooling to room temperature, the suspension was partitioned between ethyl acetate and water. The aqueous phase was extracted with ethyl acetate and the combined organic layers were dried over MgSO 4 , concentrated under reduced pressure and dried to yield the desired N-methylated indole ester (6) as a beige solid in a 96-99% yield.
5.1.3. General synthetic procedure for 1-(1H-indol-2-yl)-2-arylketones (7-10, 12) 43 An oven-dried flask was purged with argon while hot, then allowed to cool down to room temperature under argon and 400 charged with dry THF (2 mL/mmol of starting indole 3/6) and diisopropylamine (4.0 equiv). The solution was cooled to À78°C in a dry ice/isopropanol bath and n-butyl lithium, 1.6 M solution in hexanes (4.0 equiv), was added to give a bright yellow solution. The mixture was stirred for 30 min below À60°C whereupon a solution of picoline or another appropriate reagent with an ionizable methyl(ene) group (4.0 equiv) in THF (2 mL/mmol of starting indole 3 or 6) was added to give a yellow to red colored mixture. During a further 30 min, the bath temperature was allowed to rise to approx. 0°C during which time the reaction mixture became a 410 yellow to red suspension. The temperature was then kept at 0°C (using an ice/water bath) for an additional 30 min. At this point, a solution of the indole-2-carbonyl compound 3/6 (1.0 equiv) in THF (4 mL/mmol) was added dropwise over the flask wall. The reaction mixture darkened (dark purple to dark brown color in most cases) and was then allowed to attain room temperature overnight. At 18 h (unless otherwise stated) after the addition of the indole component, the reaction was quenched with saturated aqueous ammonium chloride solution (10 mL/mmol of starting compound 3/6) and stirred for several minutes. Upon partition be-420 tween ethyl acetate and water, the aqueous phase was extracted twice with dichloromethane and the combined organic layers were dried over MgSO 4 . The title products were purified by chromatography (the products typically eluted with 70-80% of ethyl acetate). The products were then precipitated by concentration of the pooled column fractions combined with the addition of cyclohexane. The precipitates formed were filtered off, washed twice with cyclohexane and dried at 40°C in vacuo to yield analytically pure samples. The following compounds were prepared in this way: 
1-(5-Methyl-1H-indol-2-yl)-2-pyridin-3-yl-ethanone (7i).
Prepared from commercial 5-methyl-1H-indole-2-carboxylic acid (482 mg, 2.75 mmol) and 3-picoline via corresponding acyl chloride 3i (method A 
1-(5-Methoxy-1H-indol-2-yl)-2-pyridin-3-yl-ethanone
(7j) and 1-(7-methoxy-1H-indol-2-yl)-2-pyridin-3-yl-ethanone (7q) 43 . Prepared from a $1:1 mixture (method B; 208 mg, 0.95 mmol) of 5-methoxy-1H-indole-2-carboxylic acid ethyl ester (3j) and 7-methoxy-1H-indole-2-carboxylic acid ethyl ester (3q) and 3-picoline. The two final products were separated by chromatography. 7j: (Sundberg 1978 46 . Prepared according to a literature procedure. A suspension of tetrakis(triphenylphosphine)palladium (0) (7 mg, 6 lmol) in a mixture of 1 M potassium carbonate (0.8 mL), ethanol (0.8 mL) and toluene 610 (0.8 mL) was added to a stirred suspension of bromoindole 7h (38 mg, 0.12 mmol) and phenylboronic acid (33 mg, 0.26 mmol) in a 1:1 mixture of toluene and ethanol (0.8 mL). The (initially ochre colored) suspension was heated at reflux temperature for 20 h, allowed to cool down to room temperature and diluted with ethyl acetate. Evaporation with silica and chromatographic purification afforded the title product as a bright yellow solid (12 mg, 32%). LC-MS R t 6.5 min (method 1), 10 3 ). 13 The flask was evacuated and back-filled with hydrogen gas (repeated three times). The suspension was stirred at room temperature for 45 min (until TLC indicated reaction completion) and filtered through Celite 545. The filter was extensively washed with ethyl acetate and the combined filtrate and washings were concentrated under reduced pressure. Chromatographic purification (the title product eluted with 80-90% ethyl acetate) afforded the title hydroxyindole 7s as a light brown half-solid in a 53% (24 mg) yield. The coding region for human IDO (Ala2-Gly403) was cloned into a derivative of plasmid pET9 (Novagen). The recombinant plasmid, pETIDO, encodes a histidine tag at the N-terminus of IDO. Bacterial strain BL21 AI (Invitrogen) was used for overexpression of IDO and 980 transformed with the pETIDO plasmid. The transformed cells were grown on a rotary shaker at 37°C and 220 rpm to an OD600 of 1.2, in LB medium supplemented with 25 lg/mL kanamycin, 50 lg/mL L-tryptophan and 10 lM bovine hemin (Sigma). The culture was cooled in a water/ice bath and supplemented again with 50 lg/ mL L-tryptophan and 10 lM bovine hemin. The expression of Histagged IDO was induced by the addition of 1% (w/v) arabinose. Induced cells were grown at 20°C and 60 rpm for 20 h. Cells (1 L culture) were collected by centrifugation, resuspended in 40 mL of 25 mM Mes, 150 mM KCl, 10 mM imidazole, and protease inhib-990 itors (complete EDTA free, Roche Applied Science) (pH 6.5), and disrupted with a French press. The extract was clarified by centrifugation and filtration on a 0.22 lm filter. The enzyme was purified by IMAC using Ni2þ as a ligand and an IMAC HITRAP column (5 mL, GE Healthcare). Briefly, the extract was loaded on the column with 25 mM Mes, 150 mM KCl, and 10 mM imidazole (pH 6.5). The column was washed with 50 mL of the same buffer with the imidazole concentration adjusted to 100 mM. Finally, the protein was eluted with 25 mM Mes, 150 mM KCl, and 50 mM EDTA (pH 6.5). The buffer was then exchanged into 25 mM Mes and 150 mM KCl (pH 6.5) 1000 using a HITRAP desalting column (GE Healthcare). The purity of the enzyme was estimated to be >95% based on the SDS-PAGE gel and Coomassie blue staining. The ratio of absorbance at 404 nm to that at 280 nm of the protein was around 1.9.
Assay buffer
Assay buffer was composed of Phosphate Buffer 50 mM (pH Hydrogen peroxide solution (Sigma-Aldrich, H1009) is prepared at a concentration of 10 mM in water.
Enzymatic assay
Enzymatic Assay was performed in 384 Wells microplates (Greiner bio one, 781108). Ninety five microliters of reaction buffer with L-Tryptophan substrate at 100 lM and compound to be tested are added in the microplate. The optical density at 320 nm of this mixture is first recorded as a baseline with a Spectramax plus spectrophotometer (Molecular Devices). The hIDO enzyme (0.375 lg in 5 ll) is then added to the mixture. After 60 min incubation at room 1020 temperature, the reaction is stopped by the addition of hydrogen peroxide (1 mM) and a second optical reading at 320 nm is performed. The difference between the two density values reflects the level of tryptophan degradation and is used to calculate the percentage of IDO inhibition relative to the reference inhibitor 1-MT. Dose-response inhibition of IDO is analyzed using GraphPad Prism 4 program (GraphPad Software Inc.).
Cellular tests
Cell line
A plasmid construct encoding murine IDO was transfected into 1030 mouse mastocytoma line P815B. Clone P185B-mIDO clone 6 (Uyttenhove et al, 2003), which overexpresses IDO, was selected and used for the cellular assay. Mouse IDO shares a 62% sequence identity with human IDO, and the active site residues are 100% conserved.
Assay
The assay was performed in 96-well flat bottom plates seeded with 2 Â 10 In those conditions, about 50% of the initial amount of tryptophan was degraded in the absence of inhibitor, and an equimolar amount of kynurenine was produced. The percentages of inhibition of tryptophan degradation and kynurenine production by the compounds were calculated in reference to this maximal activity. The initial wells containing the cells in the remaining volume of 50 ll were used to estimate cell viability in a classical MTT assay. To that end, 50 ll of culture medium (Iscove medium with 10% FCS and amino acids) were added to the wells together with 50 ll of MTT. After 3-4 h of incubation at 37°C, 100 ll of SDS/DMF were 1060 added to dissolve the crystals of formazan blue and the absorbance at 570/650 nm was measured after overnight incubation at 37°C.
X-ray determination
X-ray measurements were performed on a Gemini Ultra R system (4-circle kappa platform, Ruby CCD detector) using MoKa radiation (k = 0.71073 Å) for the two compounds. After mounting and centering of the single crystals on the diffractometer, cell parameters were estimated from a pre-experiment run and full datasets collected at room temperature. Software for data reduction was CrysAliPro. 52 Structures were solved by direct methods 1070 from SHELXS-97 program 53 and then refined on F 2 using software. Non-hydrogen atoms were anisotropically refined and the hydrogen atoms in the riding mode with isotropic temperature factors fixed at 1.2 times U (equiv) of the parent atoms. CCDC 794450 and 794451 contain the supplementary crystallographic data for this paper and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033; or deposit@ccdc.cam.ac.uk).
Molecular modeling
Molecular modeling studies were carried out on a Linux workstation. The compounds were built using the SKETCH module implemented in SYBYL (version 8.0).
54 Docking was performed using the 3D-coordinates of TDO (pdb code 2D0T) with the help of the 35 (active site definition: residues within 7 Å around PIM). In order to take protein flexibility into account, the enzyme-inhibitor complexes were optimized using the MINIMIZE module. The minimization process uses the Powell method with the Tripos force field (dielectric constant 1r) to reach a final convergence of 0.01 kcal mol
À1
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